ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2744

Mi-RNA Profile of Active Vascular BEHÇET’S Patients

Ahmet Mesut Onat1, Ozan Gerenli2, Bunyamin Kisacik1, Mustafa Ulasli3, Gezmis Kimyon4, Yavuz Pehlivan5 and Serdar Oztuzcu6, 1Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 2Rheumatology, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey, 3Genetics, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey, 4Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 5Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, 6Genetcs, Gaziantep UniversitySchool of Medicine, Gaziantep, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, MicroRNA, ulcers and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Behçet’s Disease (BD) is a systemic vasculitis that predominantly presented with oral aphtous ulcers and additionally at least two of the following findings like genital ulcers, eye involvement, skin lesions and pathergy reaction. Vascular involvement is devastating face of BD and thrombosis of the arterial and venous system and aneurismatic arterial disease is not rare. The flares are the typical nature of BD and the pathology of the disease is mostly constructed on vasculitis. However the satisfied mechanism of BD remains unknown.  We herein tried to evaluate the micro RNA (miRNA) behavior in BD.

Methods

Eighty-five BD patients were enrolled in to the study group, which were divided to 3 groups of 20-20 and 25 with active vascular disease, active mucocutaneous disease and patients with at least 6 months remission, respectively. Additional 25 volunteers were the healthy controls and the 4 of the groups have no difference in the characteristics.  The whole study population was male, due to difficulties of finding active women BD patients. Serum samples were analyzed for miRNA with PCR assay and the data were analyzed statistically.  Active vascular patients had significantly higher CRP and ESR results than active mucocutaneous ones and they both had significantly higher levels than remission and healthy groups.

 

Active vasculer BD

Active mucocutaneous BD

Remission BD

Healthy controls

Age

32.60±4.57

32.60±6.36

35.72±9.21

32.20±1.71

Disease duration

4.30±2.71

4.25±3.31

4.68±3.21

 

CRP (mg/l)

29.35±36.47

22.53±21.38

4.92±3.11

3.1±1.8

ESR (/hour)

34.90±26.46

30.0±24.03

15.56±11.85

10.02±4.21

Results

There was no difference for any miRNA between BD patients with remission and healthy controls. The comparison of active BD patients and healthy controls revealed lower levels of miR-17-5p, miR-451A, miR-106b-5p, miR-16-5p, miR-19b-3p, miR-26b-5p, miR-93-5p, miR-20b, miR-25-3p in the disease activity. miR26b-5p was found lower only in mucocutaneous group inspite of vasculars.

Conclusion

The miRNA profile of active BDs especially the vascular group was remarkable. These miRNAs were related mainly with T and B lymphocytes and some apoptotic genes. miRNA studies might be beneficial for detecting better targets for treating the disease in the future.


Disclosure:

A. M. Onat,
None;

O. Gerenli,
None;

B. Kisacik,
None;

M. Ulasli,
None;

G. Kimyon,
None;

Y. Pehlivan,
None;

S. Oztuzcu,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mi-rna-profile-of-active-vascular-behcets-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology